Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
01/06/21 Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
01/06/21 Alkermes Announces Updates to Executive Leadership Team
12/29/20 FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
12/10/20 Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

A preliminary proxy statement providing notification matters to be brought to a vote

A preliminary proxy statement providing notification matters to be brought to a vote

A preliminary proxy statement providing notification matters to be brought to a vote

A statement of beneficial ownership of common stock by certain persons

A statement of beneficial ownership of common stock by certain persons